Wednesday, August 22, 2012

Cocoa may improve brain function




Caregivers, and healthcare professionals, here is some great information


Here is a great dementia resource for caregivers and healthcare professinals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

WebMD

Having a cocoa-rich drink every day as part of a calorie-controlled and nutritionally-balanced diet could improve brain function in older adults, according to a new study.
The Italian study, published in the American Heart Association’s journal Hypertension, included 90 elderly people who already had mild cognitive impairment (MCI), which can include difficulty with memory, language, thinking or judgment.
For eight weeks they drank a cocoa drink that had high, medium or low amounts of antioxidants called flavanols and their diet was restricted to eliminate other sources of flavanols from foods and beverages. Those who had high and medium levels of flavanols in their drink did better on tests of attention and other mental skills, compared to people who had low amounts of flavanols.

Flavanols

Flavanols can be found in tea, grapes, red wine, apples and cocoa products and have been associated with a decreased risk of dementia. The researchers say flavanols may act on the brain structure and function directly by protecting neurons from injury, improving metabolism and their interaction with the molecular structure responsible for memory. Indirectly, flavanols may help by improving brain blood flow.
Flavanols "could be one element of a dietary approach to the maintaining and improving not only of cardiovascular health, but also specifically brain health", write the researchers, including Giovambattista Desideri of Italy's University of L'Aquila.
However, he cautions that the results of the study may not apply to everyone with MCI. The study population was generally in good health without known cardiovascular disease so it would not be completely representative of all mild cognitive impairment patients. In addition, only some clinical features of mild cognitive impairment were explored in the study.

Alzheimer's

Dr Laura Phipps at Alzheimer’s Research UK said via e-mail: "Cocoa-based treatments for brain function would likely have patients queuing out the door, but this small study of flavanols is not yet conclusive. It’s not clear from the research whether other factors may have been responsible for the improvements seen in the group of people who took part.
This early-stage trial took place over a very short period, and it would be useful to see more long-term studies to investigate the lasting effects. Ultimately we would need to see the results of large-scale trials to know whether cocoa flavanols could help prevent or delay dementia.
"While we do not yet have a sure-fire way to prevent dementia, the best evidence for lowering your risk is to eat a healthy, balanced diet with plenty of fruit and vegetables. Regular exercise, keeping your blood pressure and cholesterol in check and not smoking have also been shown to reduce the risk of dementia."
Neurologist and Alzheimer's disease researcher Dr Marc Gordon of the Feinstein Institute for Medical Research in New York says: "People need to be very careful about making broad-based dietary changes based on one study."
The Italian study was supported by a grant from Mars Inc, which also supplied the powdered cocoa drinks that were used.

Monday, August 20, 2012

Caring for a loved one with mesothelioma


Caregivers and health care professionals here is some information that you will find most useful.

As a health care professional, you no doubt have cared for people with a wide range of illnesses. As a caregiver, you may have cared for a loved one with one particular sickness. Sometimes things do not make sense about a person’s illness

Your loved one or client may have dementia, heart disease, lung problems or some other disease. How do you know what to expect from person(s) you are caring for?

As a health care professional, you are trained to look for certain things. As a caregiver you and your loved one’s doctor are a team wanting the best for this person. If you and your doctor see symptoms that might indicate an illness caused by contamination of a foreign substance, you may need the services of a lawyer so you can get compensation to help pay for medical costs of the illness.

If, for example, your loved one or client has mesothelioma caused by asbestos, you may want to seek the help of a mesothelioma lawyer. Using him will not cure your loved one or client, but you can get the financial help you need and deserve.

Research Shows Glymphatic System Flushes Away Most Alzheimer's Plaque



Caregivers, and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professinals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition


Scientific American
The brain can be a messy place. Thankfully, it has good plumbing: Scientists have just discovered a cleansing river inside the brain, a fluid stream that might be enlisted to flush away the buildup of proteins associated with Alzheimer's, Huntington's and other neurodegenerative disorders.
The researchers, based at the University of Rochester (U.R.), University of Oslo and Stony Brook University, describe this new system in the journal Science Translational Medicine today. The study adds to the evidence that the star-shaped cells called astrocytes play a leading role in keeping the nervous system in good working order.
In most of the body, a network of vessels carry lymph, a fluid that removes excess plasma, dead blood cells, debris and other waste. But the brain is different. Instead of lymph, the brain is bathed in cerebrospinal fluid. For decades, however, neuroscientists have assumed that this fluid simply carries soluble waste by slowly diffusing through tissues, then shipping its cargo out of the nervous system and eventually into the body's bloodstream. Determining what's really going on has been impossible until recently.
In this study, researchers led by U.R. neuroscientist Maiken Nedergaard have identified a second, faster brain-cleansing system. Nedergaard an expert in non-neuronal brain cells called glia, has long suspected that these cells might play a role in brain cleansing.
Nedergaard and colleagues studied live mice with holes drilled into their skulls to gain an unobstructed view. To see how waste is carried by cerebrospinal fluid in a living mouse, they injected the mice with radioactive molecules that could be traced using laser-scanning technology.
The molecules' journey began after being injected into the subarachnoid space, a cavity between membranes covering the brain and spinal cord. The researchers observed that, like a river, cerebrospinal fluid carried these molecules rapidly along specific channels. Glial cells along the outside of arteries form these channels, creating a flume for cerebrospinal fluid that follows the brain's blood vessels. In addition, the researchers found that these glial cells mediate the channel's activity, assisting the flow of fluid through the channel.
From channels alongside arteries, the tracer-bearing fluid then passes through brain tissues. At the other end of tissues, it flows into similar channels along veins. The fluid follows these veins then either returns to the subarachnoid space, enters the bloodstream or eventually drains into the body's lymphatic system. The researchers christened the network the "glymphatic" system, a nod to both glial cells and its functional similarity to the lymphatic system.
U.R. neuroscientist and lead author Jeff Iliff notes several surprises in the study: "I didn't think we would see these jets of fluid going through the brain," Iliff says. In addition, he explains that previous conception of cerebrospinal fluid's role in waste removal suggested that the process was one-way, sending particle-carrying fluid from the brain into the body. Instead, they observed a recycling, as much as 40 percent of the fluid returned to the brain.
As a test of their work, the researchers injected proteins called amyloid beta into mice's brains. In Alzheimer's, this protein—present in all healthy brains—can accumulate and clump, developing into cell-damaging plaque. The researchers compared mice with a normal glymphatic system to those with a disabled gene that prevented glial cells from assisting in the fluid flow. They found that in the normal mice, the protein rapidly cleared from the brain along these channels, but amyloid removal diminished in the gene-altered animals.
*Iliff hypothesizes that a faulty glymphatic system may bear the blame for the over-accumulation of proteins seen in Alzheimer's, amyotrophic lateral sclerosis, Huntington's and other neurodegenerative disorders—and further study may even reveal a way to dispose of these clumps.
Jaleel Miyan, a neurobiologist at the University of Manchester in England who did not participate in this research, stressed the significance of this finding by characterizing the analogy with the lymphatic system as inadequate: "What they have demonstrated is actually far more extensive and important to CSF [cerebrospinal fluid] biology." The study clarifies discrepancies in past research and may lead to a better understanding of the functioning of the glymphatic system as a possible cleanser of the neural toxins that inevitably accrete and do damage as we age.

Saturday, August 18, 2012

HiV drug may slow memory loss


Caregivers, and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professinals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

WebMD

By 
WebMD Health News

A drug that's already been approved by the FDA for use in HIV patients may also help slow the decline of memory and mental function experienced by people who are in the early stages of Alzheimer's disease.
The drug, Egrifta, stimulates the release of human growth hormone from the brain's pituitary gland. It was approved by the FDA in 2010 to help correct the abnormal distribution of body fat that often occurs in patients who live with HIV.
A new study published in the Archives of Neurology suggests it may also slowmemory loss in people who have mild cognitive impairment (MCI), a condition that often precedes full-blown Alzheimer's disease.
For the study, researchers assigned adults between the ages of 55 and 87 to get either nightly injections of Egrifta or a placebo for five months. Some were healthy and showed no evidence of memory problems on a battery of mental function tests. Others showed MCI, or memory loss that was worse than expected for their age but was not yet severe enough to interfere with daily living.
A total of 137 patients -- 76 who were healthy and 61 with MCI -- finished the study. Researchers brought them back to the lab four times: at the start of the study, then at weeks 10, 20, and then another 10 weeks after the nightly shots stopped.
At each visit, their blood was drawn. In addition, they took a battery of tests that measured different skills used in mental processing and short-term recall of words, shapes, and facts. Researchers also asked them about their mood and sleeping patterns.
In both healthy adults and those with MCI, those taking Egrifta fared better than their counterparts who took placebo injections.
Healthy adults saw their executive function improve by about 200% over their peers who got a placebo. Executive function refers to the brain's ability to manage attention and concentration, to switch between thoughts, and use working memory to plan and strategize tasks.
Adults with MCI still saw their executive function slip over the five months of the study, but their declines were not as large as those in the placebo group.
"Their expected decline was cut in half," says researcher Laura D. Baker, PhD, apsychiatrist at the University of Washington School of Medicine in Seattle.
By the end of the study, people on the drug were also better able to recall words and details of stories a bit better than people on the placebo, though the differences between the groups were not significant.

How Egrifta Works

Egrifta is a close copy of a chemical that's already made by the body called growth-hormone-releasing hormone. As the name implies, it stimulates the production of human growth hormone (HGH). Human growth hormone, in turn, triggers the release of a whole cascade of other hormones including insulin and its close cousin, insulin-like growth factor.

How Egrifta Works continued..

Insulin is probably best known for its role in regulating blood sugar, but it also has important work in the brain. In the brain, insulin stimulates the growth of new nerves and protects existing nerves from damage. Insulin levels in the brain fall with age, and previous studies have found that they're especially low in the brains of patients with Alzheimer's and other kinds of dementia.
The same group of researchers involved in the study has been testing whether inhaled insulin can reverse memory loss in Alzheimer's patients.
Egrifta may boost insulin in the brain less directly, and that could be a good thing, Baker says.
"What's so nice about this particular strategy is that it stimulates a whole cascade of hormone activities. Once this whole cascade is stimulated, it behaves normally, as it does when we're younger adults. So all we're kind of doing is boosting the system and letting it do what it does best," she says.
"It also shuts itself off when levels of one hormone or another get too high," Baker tells WebMD, so the levels always stay within a more normal range.

Risk, Side Effects, and Cost to Be Considered

Should a larger, longer study confirm the benefits of the medication for patients with early memory loss, it wouldn't come cheap.
Baker says that given at the dosages used in the study, the drug costs about $750 a day, or more than $22,500 for a 30-day supply.
"Of course that's not feasible," she says. "No health plan would ever pay for this."
She says drug companies are hard at work trying to find a way to make a less expensive version.
Side effects were reported by 68% of people on Egrifta -- twice the rate of adverse events experienced by those on the placebo injections. Side effects were mostly mild. They included skin reactions like itching, redness, and stinging around the injection site. It was also common for people to report increased joint pain and stomach upset.
There are already products at vitamin and health foods stores that claim to boost growth-hormone-releasing hormone, but Baker cautions that they could do so dangerously.
But, she says, there is a far less expensive and less risky way to get virtually the same degree of benefit as was seen with this pricey drug: Exercise.
"We completed a study last year testing exercise for brain function in people with mild cognitive impairment," Baker says. "We had the same improvements in executive function. We used the same tests in both studies, and we saw the same benefits."
How much exercise is needed to get the benefit? In her previous study, which was published in 2010 in the Archives of Neurology, people engaged in aerobic exercisefor 45 to 60 minutes at least four days of the week for six months.
"Up to this point, this is the most potent way to slow things down or improve cognition," she says.

Thursday, August 16, 2012

Single brain trauma affects an enzyme associated with Alzheimer's disease


Caregivers, and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professinals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

Tufts Now


A study, performed in mice and utilizing post-mortem samples of brains from patients with Alzheimer’s disease, found that a single event of a moderate-to-severe traumatic brain injury (TBI) can disrupt proteins that regulate an enzyme associated with Alzheimer’s. The paper, published in the Journal of Neuroscience, identifies the complex mechanisms that result in a rapid and robust post-injury elevation of the enzyme BACE1 in the brain. These results may lead to the development of a drug treatment that targets this mechanism to slow the progression of Alzheimer’s disease.
“A moderate-to-severe TBI, or head trauma, is one of the strongest environmental risk factors for Alzheimer’s disease. A serious TBI can lead to a dysfunction in the regulation of the enzyme BACE1. Elevations of this enzyme cause elevated levels of amyloid-beta, the key component of brain plaques associated with senility and Alzheimer’s disease,” says first author Kendall Walker, postdoctoral associate in the department of neuroscience at Tufts University School of Medicine (TUSM). 
Moderate-to-severe TBIs are caused most often by traumas such as severe falls or motor vehicle accidents that result in a loss of consciousness. Not all traumas to the head result in a TBI. According to the Centers for Disease Control and Prevention, each year 1.7 million people sustain a TBI. Concussions, the mildest form of a TBI, account for about 75 percent of all TBIs. Studies have linked repeated head trauma to brain disease, and some previous studies have linked single events of brain trauma to brain disease, such as Alzheimer’s. Alzheimer’s disease currently affects as many as 5.1 million Americans and is the most common cause of dementia in adults age 65 and over.
Building on her previous work, Giuseppina Tesco, an assistant professor of neuroscience in the School of Medicine, led a research team that first used an in vivo model to determine how a single episode of TBI could alter the brain. In the acute phase (first two days) following injury, levels of two intracellular trafficking proteins (GGA1 and GGA3) were reduced, and an elevation of BACE1 enzyme level was observed.
Next, in an analysis of post-mortem brain samples from patients with Alzheimer’s disease, the researchers found that GGA1 and GGA3 levels were reduced while BACE1 levels were elevated in the brains of Alzheimer’s disease patients compared to the brains of people without Alzheimer’s disease, suggesting a possible inverse association.
In an additional experiment using a mouse strain genetically modified to express the reduced level of GGA3 that was observed in the brains of Alzheimer’s disease patients, the team found that one week following traumatic brain injury, BACE1 and amyloid-beta levels remained elevated even when GGA1 levels had returned to normal. The research suggests that reduced levels of GGA3 were solely responsible for the increase in BACE 1 levels and therefore the sustained amyloid-beta production observed in the sub-acute phase, or seven days, after injury.
“When the proteins are at normal levels, they work as a clean-up crew for the brain by regulating the removal of BACE1 enzymes and facilitating their transport to lysosomes within brain cells, an area of the cell that breaks down and removes excess cellular material. BACE1 enzyme levels may be stabilized when levels of the two proteins are low, likely caused by an interruption in the natural disposal process of the enzyme,” said Tesco, who is also member of the neuroscience program faculty at the Sackler School of Graduate Biomedical Sciences at Tufts.
“We found that GGA1 and GGA3 act synergistically to regulate BACE1 post-injury. The identification of this interaction may provide a drug target to therapeutically regulate the BACE1 enzyme and reduce the deposition of amyloid-beta in Alzheimer’s patients,” she continued. “Our next steps are to confirm these findings in post-mortem brain samples from patients with moderate-to-severe traumatic brain injuries.”

Tuesday, August 14, 2012

Butter Flavoring Linked to Alzheimer’s Disease


Caregivers, and healthcare professionals, here is some great information

Here is a great dementia resource for caregivers and healthcare professinals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

Food Poisoning Alert

A new study published in Chemical Research in Toxicology showed that the butter flavoring diacetyl (DA) increases the type of protein clumping linked to Alzheimer’s disease. The chemical is found in many processed foods, including microwave popcorn, snack foods, baked goods, and margarine. In fact, the researchers say that diacetyl is “ubiquitous” in the modern diet.
The study’s authors are troubled about chronic exposure that industry workers have to DA. That exposure may lead to long-term neurological damage. DA easily traversed the blood-brain barrier, which usually keeps substances from entering the brain itself. Scientists do not know if consuming DA in products like microwave popcorn can cause problematic levels of the chemical in the body.
Diacetyl’s structure is similar to other substances that makes beta-amyloid proteins clump in the brain. That clumping is indicative of Alzheimer’s disease. In addition, DA prevented a protective protein that helps keep nerve cells healthy from reaching the brain.
Diacetyl is a natural byproduct of fermentation and is also synthesized for use in the food industry. The United States Occupational Safety and Health Administration (OSHA) has written hazard communication guidance for the chemical. That guidance says that “a number of employees exposed to food flavorings containing diacetyl (FFCD) have developed serious respiratory illness presenting with persistent dry cough, wheezing, shortness of breath upon exertion, and fixed airways obstruction on spirometry. Several employees have been diagnosed with asthma or bronchiolitis obliterans.”
The National Institute for Occupational Safety and Health (NIOSH) has investigated the occurrence of severe lung disease in employees at microwave popcorn packaging plants and flavorings manufacturing facilities in 2003 and 2007. This latest research on the link between DA and Alzheimer’s Disease strengthens the concern about this chemical and the health of industry workers.

Sunday, August 12, 2012

Alzheimer's Progression Slower After 80


Caregivers, and healthcare professionals, here is some great information


Here is a great dementia resource for caregivers and healthcare professinals,


Your residents will love the Amazon Kindle Fire


Here is information on being the best caregiver you can be


Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition

By Steven Reinberg
HealthDay Reporter
(HealthDay News) -- The deadly march of Alzheimer's disease is slower in people aged 80 or older than the younger elderly, researchers have found.

The risk of developing Alzheimer's disease increases with age, and by 85, the risk is about 50 percent. But those who develop the progressive brain disorder that late in life will experience a less aggressive disease than those whose symptoms appear at 60 or 70 years, according to investigators at the University of California, San Diego.
Lead researcher Dominic Holland from the university's neurosciences department said doctors will need to consider these findings when assessing older patients for Alzheimer's disease.
"Methods for early detection, which will rely on biomarkers as well as mental ability, will need to take into account the age of the individuals being assessed," he said. Because the "old" elderly may deteriorate at a slower pace than younger patients, doctors may not realize these people are suffering from Alzheimer's disease.
The findings also have implications for clinical trials evaluating potential Alzheimer's treatments and cost-of-care projections for different Alzheimer's patients, Holland and other experts say.
Currently, no effective treatments exist to slow or cure Alzheimer's disease, which gradually destroys brain cells and robs people of memory, and their ability to communicate and carry out everyday tasks.
The report was published Aug. 2 in the online journal PLoS One.
To study Alzheimer's disease progression, Holland and colleagues used data from the Alzheimer's Disease Neuroimaging Initiative study. They looked at more than 700 people aged 65 to 90, some with normal mental functioning, some with mild signs of dementia and others suffering from Alzheimer's.
Participants were tested every 6 or 12 months.
The researchers found that younger Alzheimer's patients lost their mental abilities faster than older patients.
These declines among younger patients paralleled the accelerated rate of brain tissue loss and the increase in a spinal-fluid indicator of Alzheimer's seen among the younger age group, compared with older patients, the study authors added.
The researchers aren't sure why Alzheimer's is more aggressive in younger patients. One explanation might be that the older patients have been declining at that slower rate over a longer time, with some unknown factor keeping symptoms at bay, they suggest.
Another possibility is that the older patients have dementia plus Alzheimer's, which might stall the full effect of Alzheimer's on the brain. But such a diagnosis must be made with an autopsy, which is the only way Alzheimer's is accurately diagnosed, Holland noted.
Alzheimer's disease currently affects an estimated 5.6 million Americans, and that number is expected to triple by 2050 as the baby boom generation ages.
The finding that the earlier one develops the disease, the more aggressive it is isn't good news for those younger elderly patients who will suffer the worsening loss of their mental abilities for a long time, Holland said.
Another expert said the findings may affect both health cost projections and clinical trials.
"This is an extremely important paper with implications for both the projections of cost of care for Alzheimer's disease and for planning clinical trials," said Dr. Sam Gandy, associate director of the Mount Sinai Alzheimer's Disease Research Center at the Mount Sinai School of Medicine in New York City.
If the clinical picture in the over-85 population is milder than what is typical in younger populations, those older patients would remain independent longer, and the projections for the economic burden to the health care system should be adjusted, he said.
"The annual cost now is $200 billion in the U.S.; the projection is $1 trillion annually by 2050," Gandy said.
"Maybe that $1 trillion is really only $500 to $750 billion. Still catastrophic, but it is worth considering this in projection," he added.
Equally important, if the rate of decline is slower in 85-year-olds than in 65-year-olds, that must be taken into account when recruiting for clinical trials, Gandy said.
For example, if all the patients receiving a drug were over 85 and all the patients receiving an inactive placebo were much younger, it might appear the drug was working when, in fact, the populations were improperly matched, Gandy pointed out.
"We have known that we wanted populations to be as identical as possible, but we didn't really know of this specific phenomenon before," he said.
More information
For more information on Alzheimer's disease, visit theAlzheimer's Association.

Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info